H.C. Wainwright reaffirmed a Buy rating on Axsome Therapeutics on September 2, 2025.
2 reports, 2 independent
Updated Jul 18
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
H.C. Wainwright reaffirmed a Buy rating on Axsome Therapeutics on September 2, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Mark Coleman sold shares of Axsome Therapeutics, alongside updated rating coverage.1 source
H.C. Wainwright reaffirmed Buy rating on Axsome Therapeutics.1 source
Keep exploring
The entities involved
-
Axsome Therapeutics
American biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- tickerreport.com
- Insider MonkeyH.C. Wainwright Reaffirms Buy on Axsome (AXSM) Following Generic Challenge to Portfolio Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best mid-cap stocks with huge upside potential. H.C. Wai